Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks

Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks

PR Newswire

LOS ANGELES, July 14, 2026

Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome Measures Consistent with Durable Treatment Benefit Through 18 Months LOS ANGELES, July 14, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced extended data from patients who continued treatment under a compassionate use Special Access Scheme (SAS) following its completed Phase 2a trial evaluating Tazbentetol (SPG302) for the treatment of Alzheimer's disease (AD). Once-daily treatment with Tazbentetol, a first-in-class synaptic regenerative investigational therapy, initially demonstrated rapid improvement in multiple measures of cognition during placebo-controlled and open label extension periods of the Phase 2a trial and has shown sustained improvement for up to 84 weeks in patients participating in the SAS program.